Diffuse optical tomography of the breast: A potential modifiable biomarker of breast cancer risk with neoadjuvant chemotherapy

Mirella L. Altoe, Alessandro Marone, Hyun K. Kim, Kevin Kalinsky, Dawn L. Hershman, Andreas H. Hielscher, Richard S. Ha

    Research output: Contribution to journalArticlepeer-review

    Abstract

    The purpose of this study is to evaluate whether a diffuse optical tomography breast imaging system (DOTBIS) can provide a comparable optical-based image index of mammographic breast density, an established biomarker of breast cancer risk. Oxyhemoglobin concentration (ctO2Hb) measured by DOTBIS was collected from 40 patients with stage II-III breast cancer. The tumor-free contralateral breast was used for this evaluation. We observed a moderate positive correlation between the patient’s mammogram density classification and ctO2Hb, rs = 0.486 (p = 0.001). In addition, significant reduction in ctO2Hb levels were noted during neoadjuvant chemotherapy treatment (p = 0.017). This observation indicates that ctO2Hb levels measured by DOTBIS could be a novel modifiable imaging biomarker of breast cancer risk and warrants further investigation.

    Original languageEnglish (US)
    Pages (from-to)4305-4315
    Number of pages11
    JournalBiomedical Optics Express
    Volume10
    Issue number8
    DOIs
    StatePublished - Aug 1 2019

    ASJC Scopus subject areas

    • Biotechnology
    • Atomic and Molecular Physics, and Optics

    Fingerprint Dive into the research topics of 'Diffuse optical tomography of the breast: A potential modifiable biomarker of breast cancer risk with neoadjuvant chemotherapy'. Together they form a unique fingerprint.

    Cite this